Skip to main
DYN
DYN logo

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 26 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Dyne Therapeutics Inc. has demonstrated significant advancements in its clinical pipeline, with DYNE-251 showing a ~7% increase in dystrophin expression and favorable safety outcomes during Phase I trials. Additionally, DYNE-101 has delivered meaningful improvements in disease biomarkers and functional outcomes, indicating a positive trajectory for the therapeutic's efficacy and potential accelerated approval in 2026. The company's ability to enrich patient groups and achieve stable dystrophin levels further reinforces the promising clinical profile of its therapies, suggesting a strong potential for success in future clinical advancements.

Bears say

Dyne Therapeutics faces significant financial challenges, primarily due to concerns regarding the efficacy and safety profiles of its therapeutic candidates, particularly DYNE-101 and DYNE-251, with recent data indicating a stark decline in efficacy over time. Additionally, potential payer headwinds related to reimbursements for DYNE-251 following prior treatments further complicate the outlook, posing risks to revenue generation. Moreover, any emerging safety concerns during clinical trials could severely hinder commercial uptake and negatively impact the company's stock performance.

Dyne Therapeutics (DYN) has been analyzed by 26 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 26 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.37, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.37, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.